Orion Corporation and Asahi Kasei enter into global strategic collaboration
(Thomson Reuters ONE) -
Press Release 22 June 2016 at 8.00 a.m. EEST
Orion Corporation and Asahi Kasei enter into global strategic collaboration
Orion Corporation, a Finnish pharmaceutical and diagnostics company, announced
today that it has entered into a global strategic collaboration agreement with
Japanese Asahi Kasei Pharma for the discovery, development and commercialisation
of assets in pain management.
The agreement comprises a total of four discovery phase candidates, two from
Asahi Kasei and two from Orion. The collaboration allows both companies to
exclusively license the others' development-ready programs at pre-determined
stages. The companies will co-develop the assets coming out of this
collaboration and share all development costs.
Orion will have exclusive marketing rights in Europe and Central-Asia, while
Asahi Kasei will retain exclusive marketing rights for East Asia, Southeast Asia
and South Asia (excluding Afganistan and Pakistan). The companies will pay cross
royalties to each other on sales from their respective territories, and will
mutually decide the most effective method to maximise product opportunities in
rest of the world (ROW) territories, including USA, and share ROW revenues.
"I am very pleased with the collaboration agreement with Asahi Kasei. By joining
forces and resources we aim to bring new innovative treatment options for the
benefit of patients faster and more efficiently. The agreement is also perfectly
in line with Orion's R&D strategy to focus on risk-and-reward-sharing
partnerships. We look forward to developing new pain management therapies for
the patients jointly with Asahi Kasei", says Reijo Salonen, MD, PhD, Senior Vice
President, Pharmaceutical Research and Development and Chief Medical Officer at
Orion Corporation.
About Asahi Kasei Pharma
Asahi Kasei Pharma Corporation, headquartered in Tokyo, Japan, is a research-
based health care innovator that discovers, develops, manufactures, and markets
pharmaceuticals and diagnostic products. Asahi Kasei Pharma is a wholly owned
business unit of Asahi Kasei Corporation, a US$18 billion technology company
that provides innovative, science-based solutions to a diverse range of markets
including health care, chemicals and fibers, housing and construction materials,
and electronics. For more information, please visit the Asahi Kasei Corporation
website at www.asahi-kasei.co.jp.
About Orion
Orion is a globally operating Finnish company developing pharmaceuticals and
diagnostic tests - a builder of well-being. Orion develops, manufactures and
markets human and veterinary pharmaceuticals, active pharmaceutical ingredients
and diagnostic tests. The company is continuously developing new drugs and
treatment methods. The core therapy areas of Orion's pharmaceutical R&D are
central nervous system (CNS) disorders, oncology and respiratory for which Orion
develops inhaled Easyhaler® pulmonary drugs.
Orion's net sales in 2015 amounted to EUR 1,016 million and the Company had
about 3,400 employees. Orion's A and B shares are listed on Nasdaq Helsinki.
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
Twitter: (at)OrionPharma & (at)OrionCorpIR
Further information:
Reijo Salonen, SVP, Pharmaceutical Research and Development and Chief Medical
Officer, Orion Corporation
tel. +358 50 966 3647
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Orion Oyj via GlobeNewswire
[HUG#2022123]
Unternehmensinformation / Kurzprofil:
Datum: 22.06.2016 - 07:00 Uhr
Sprache: Deutsch
News-ID 479253
Anzahl Zeichen: 4254
contact information:
Town:
Espoo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 342 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Orion Corporation and Asahi Kasei enter into global strategic collaboration"
steht unter der journalistisch-redaktionellen Verantwortung von
Orion Oyj (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
